Skip to main content
SpringerLink
Log in

Angiotensinogen variants and human hypertension

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The research on molecular genetics of human hypertension aims to identify the loci involved in the regulation o blood pressure, detect gene variants within the identifie loci, associate them with intermediate phenotypes, and ultimately estimate their quantitative effects on blood pressure level and their interaction with main environ mental factors. So far, the angiotensinogen (AGT) gene is one of the few candidate genes that has been investigated using these multiple statistical, clinical, and biochemical strategies. A highly polymorphic dinucleotide GT repeat (80% heterozygosity) has been used in several linkage studies. Other diallelic polymorphisms, located in the 59 regulatory region of the gene in intronic and exonic sequences, have been described, which were then used i association studies in different clinical settings. Positiv associations between the M235T and the G-6A polymor phisms and plasma angiotensinogen levels indicates a path way by which the AGT locus could be involved in essential hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Corvol P, Jeunemaitre X: Molecular genetics of human hypertension: role of angiotensinogen. Endocr Rev 1997,18:662–677.

    Article  PubMed  CAS  Google Scholar 

  2. Lander ES, Schork NJ: Genetic dissection of complex traits. Science 1994, 265:2037–2048.

    Article  PubMed  CAS  Google Scholar 

  3. Kotelevtsev YV, Clauser E, Corvol P. Dinucleotide repeat polymorphism in the human angiotensinogen gene Nucl Acids Res 1991,19:6978.

    Article  PubMed  CAS  Google Scholar 

  4. Jeunemaitre X, Soubrier F, Kotelevtsev YV: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71:169–180.

    Article  PubMed  CAS  Google Scholar 

  5. Caulfield M, Lavender P, Farrall M, et al.: Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994, 330:1629–1633.

    Article  PubMed  CAS  Google Scholar 

  6. Brand E, Chatelain N, Keavney B, et al.: Evaluation of the angiotensinogen locus in human essential hypertension: a European study. Hypertension 1998, 31:725–729. This large study reevaluated the relationship of the angiotensinogen locus and essential hypertension by analysis of 350 European families comprising 630 affected sibling pairs. The absence of linkage demonstrates the probably mild effect of the AGT locus and the difficulty to identify susceptibility genes by this method in essential hypertension.

    PubMed  CAS  Google Scholar 

  7. Niu T, Xu X, Rogus J, et al.: Angiotensinogen gene and hypertension in Chinese. J Clin Invest 1998, 101:188–194. This is the first large familial study of the AGT locus in a well-defined Chinese population. Negative results were obtained using the affected sib pair method.

    PubMed  CAS  Google Scholar 

  8. Atwood LD, Kammerer CM, Samollow PB: Linkage of essential hypertension to the angiotensinogen locus in Mexican Americans. Hypertension 1997, 30:326–330.

    PubMed  CAS  Google Scholar 

  9. Caulfield M, Lavender P, Newell-Price J, et al.: Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J Clin Invest 1995, 96:687–692.

    PubMed  CAS  Google Scholar 

  10. Rotimi C, Morrison L, Cooper R, et al.: Angiotensinogen gene in human hypertension. Lack of an association of the 235T allele among African Americans. Hypertension 1994, 24:591–594.

    PubMed  CAS  Google Scholar 

  11. Bloem LJ, Manatunga AK, Tewksbur DA: The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995, 95:948–953.

    PubMed  CAS  Google Scholar 

  12. Jeunemaitre X, Charru A, Chatellier A, et al.: M235T variant of the human angiotensinogen gene in unselected hypertensive patients. J Hypertens 1993, 11:S80-S81.

    Article  CAS  Google Scholar 

  13. Schmidt S, Sharma AM, Zilch O, et al.: Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. Nephrol Dial Transplant 1995,10:1145–1148.

    PubMed  CAS  Google Scholar 

  14. Jeunemaitre X, Inoue I, Williams C, et al.: Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 1997, 60:1448–1460. Extensive study of 10 diallelic polymorphisms and of the AGT microsatellite marker in two large case-control studies from France and Japan. Strong linkage disequilibrium was found allowing the delineation of six major haplotypes and an ancestral allele comprising the - 6A and 235T polymorphisms.

    PubMed  CAS  Google Scholar 

  15. Tiret L, Blanc H, Ruidavets JB, et al.: Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: th PEGASE study. Projet d’Etude des Genes de l’Hypertension Arterielle Severe a moderee Essentielle. J Hypertens 1998,16:37–44.

    Article  PubMed  CAS  Google Scholar 

  16. Schunkert H, Hense HW, Gimenez-Roqueplo AP, et al.: The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997, 29:628–633. This study replicated the mild but significant association between the M235T polymorphism and plasma angiotensinogen and found, during three different examinations, a positive relationship between this polymorphism and the percentage of people treated for essential hypertension.

    PubMed  CAS  Google Scholar 

  17. Barley J, Blackwood A, Sagnella G, et al.: Angiotensinogen Met235-->; Thr polymorphism in a London normotensive and hypertensive black and white population. J Hum Hyperten 1994, 8:639–640.

    CAS  Google Scholar 

  18. Bennet CL, Schrader AP, Morris BJ, et al.: Cross-sectional analysis of M235T variant of angiotensinogen gene in severe familial hypertension. Biochem Biophys Res Commun 1993, 197:833–83.

    Article  Google Scholar 

  19. Fornage M, Turner ST, Sing CF, et al.: Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. Hum Genet 1995, 96:295–300.

    Article  PubMed  CAS  Google Scholar 

  20. Hingorami AD, Sharma P, Jia H, et al.: Blood pressure and the M235T polymorphism of the angiotensinogen gene. Hypertension 1996, 28:907–911.

    Google Scholar 

  21. Kiema TR, Kauma H, Rantala AO, et al.: Variation at the angiotensin-converting enzyme gene and angiotensinogen gene loci in relation to blood pressure. Hypertension 199, 28:1070–1075.

  22. Fernandez-Llama P, Poch E, Oriola J, et al.: Angiotensinogen gene M235T and T174M polymorphisms in essential hypertension: relation with target organ damage Am J Hypertens 1998, 11:439–444.

    Article  PubMed  CAS  Google Scholar 

  23. Fardella CE, Claverie X, Vignolo P: T235 variant of the angiotensinogen gene and blood pressure in the Chilean population. J Hypertens 1998, 16:829–833.

    Article  PubMed  CAS  Google Scholar 

  24. Vasku A, Soucek M, Znojil V, et al.: Angiotensin I-converting enzyme and angiotensinogen gene interaction and prediction of essential hypertension. Kidney Int 1998, 53:1479–1482.

    Article  PubMed  CAS  Google Scholar 

  25. Borecki IB, Province MA, Ludwig EH, et al.: Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study. Ann Epidemiol 1997, 7:13–21.

    Article  PubMed  CAS  Google Scholar 

  26. Frossard PM, Hill SH, Elshahat YI, et al.: Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf. Clin Genet 199, 54:285–293.

  27. Kunz R, Kreutz R, Beige J, et al.: Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 1997, 30:1331–1337. This is a meta-analysis performed on articles published between 199 and 1996 involving 5493 patients. The AGT T235 allele was found to be significantly associated with hypertension, mainly in studies with a positive family history of hypertension.

    PubMed  CAS  Google Scholar 

  28. Nishimura S, Kario K, Kayaba K, et al.: Effect of the angiotensinogen gene M235T variant on blood pressure and other cardio-vascular risk factors in two Japanese populations. J Hypertens 1995, 13:717–722.

    Google Scholar 

  29. Hata A, Namikawa C, Sasaki M, et al.: Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest 1994, 93:1285–1287.

    PubMed  CAS  Google Scholar 

  30. Kamitani A, Rakugi H, Higaki J, et al.: Association analysis of a polymorphism of the angiotensinogen gene with essential hypertension in Japanese. J Hum Hypertens 1994, 8:521–524.

    PubMed  CAS  Google Scholar 

  31. Sato N, Katsuya T, Rakugi H, et al.: Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese. Hypertension 1997, 30:321–325.

    PubMed  CAS  Google Scholar 

  32. Iwai N, Shimoike H, Ohmichi N, et al. Angiotensinogen gene and blood pressure in the Japanese population. Hypertension 1995, 25:688–693.

    PubMed  CAS  Google Scholar 

  33. Rutledge DR, Browe CS, Kubilis PS, et al.: Analysis of two variants of the angiotensinogen gene in essential hypertensive African-Americans. Am J Hypertens 1994, 7:651–654.

    PubMed  CAS  Google Scholar 

  34. Rotimi C, Puras A, Cooper R, et al.: Polymorphisms of renin angiotensinogen genes among Nigerians, Jamaicans and African Americans. Hypertension 1996, 27:558–563.

    PubMed  CAS  Google Scholar 

  35. Forrester T, McFarlane-Anderson N, et al.: Angiotensinogen and blood pressure among blacks: findings from a community survey in Jamaica. J Hypertens 199, 14:315–321.

  36. Hegele RA, Harris SB, Hanley AJ, et al.: Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. Hypertension 1997, 29:1073–1077.

    PubMed  CAS  Google Scholar 

  37. Takahashi D, Tamura K, Ushikubo T, et al.: Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis Life Sci 1997, 60:1623–1633.

    Article  PubMed  CAS  Google Scholar 

  38. Gardes J, Bouhnik J, Clauser E, et al.: Role of angiotensinogen in blood pressure homeostasis. Hypertension 1982, 4:185 189.

    PubMed  Google Scholar 

  39. Ménard J, El-Amrani AIK, Savoie F, et al.: Angiotensinogen: an attractive and underrated participant in hypertension and inflammation. Hypertension 1991, 18:705–706.

    PubMed  Google Scholar 

  40. Kim HS, Krege JH, Kluckman KD, et al.: Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A 1995, 92:2735–2739.

    Article  PubMed  CAS  Google Scholar 

  41. Phillips MI: Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 1997, 29:177–187. Excellent review on the subject of antisense inhibition and adenoassociated viral vector delivery for reduction of hypertension.

    PubMed  CAS  Google Scholar 

  42. Tomita N, Morishita R, Higaki J, et al.: Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach. J Hypertens 1995, 13:1767–1774.

    Article  PubMed  CAS  Google Scholar 

  43. Makino N, Sugano M, Ohtsuka S, et al.: Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 1998, 31:1166–1170.

    PubMed  CAS  Google Scholar 

  44. Gyurko R, Wielbo D, Phillips MI: Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept 1993, 49:167–174.

    Article  PubMed  CAS  Google Scholar 

  45. Peng JF, Kimura B, Fregly MJ, et al.: Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood. Hypertension 1998, 31:1317–1323.

    PubMed  CAS  Google Scholar 

  46. Walker WG, Whelton PK, Saito H, et al.: Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1979, 1:287–291.

    PubMed  CAS  Google Scholar 

  47. Fasola AF, Martz BL, Helmer OM: Plasma renin activity during supine exercise in offspring of hypertensive patients. J Appl Physiol 1968, 25:410–415.

    CAS  Google Scholar 

  48. Watt GCM, Harra SB, Foy CJW, et al.: Abnormalities of glucocorticoid metabolism and the renin angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure. J Hypertens 1992,10:473–482.

    Article  PubMed  CAS  Google Scholar 

  49. Ueno N, Yoshida K, Hirose S, et al.: Angiotensinogen-producing hepato-cellular carcinoma. Hypertension 1984, 6:931–933.

    PubMed  CAS  Google Scholar 

  50. Kew MC, Leckie BJ, Greeff MC: Arterial hypertension as a paraneoplastic phenomenon in hepatocellular carcinoma. Arch Intern Med 1989, 149:2111–2113.

    Article  PubMed  CAS  Google Scholar 

  51. Bloem LJ, Forou TM, Ambrosius WT, et al.: Association of the angiotensinogen gene to serum angiotensinogen in blacks and whites. Hypertension 1997, 29:1078–1082.

    PubMed  CAS  Google Scholar 

  52. Williams GH, Hollenberg NK: Non-modulating hypertension: a subset of sodium sensitive hypertension. Hypertension 1991, 17:181–185.

    Google Scholar 

  53. Williams GH, Dluhy RG, Lifton RL, et al.: Non-modulation is an intermediate phenotype in essential hypertension. Hypertension 1992, 20:788–796.

    PubMed  CAS  Google Scholar 

  54. Hopkins PN, Lifton RP, Hollenberg NK, et al.: Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 1996, 14:199–207. First demonstration of a relationship between the AGT M235T polymorphism and the nonmodulation intermediate phenotype.

    Article  PubMed  CAS  Google Scholar 

  55. Inoue I, Nakajima T, Williams CS, et al.: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997, 99:1786–1797. Extensive study demonstrating the influence of the G-6A polymorphism on the basal transcriptional activity of the AGT gene by multiple tests of promoter function in cultured cells and binding studies.

    PubMed  CAS  Google Scholar 

  56. Hüber R, Carrell RW: Implications of the three-dimensional structure of a1-antitrypsin for structure and function of serpins. Biochemistry 1989, 28:8966–8971.

    Article  Google Scholar 

  57. Cohen P, Badouaille G, Gimenez-Roquepl A-P, et al.: Selective recognition of M235T angiotensinogen variants and their determination in human plasma by monoclonal antibodybased immunoanalysis. J Clin Endocrinol Metab 1996, 81:3505–3512.

    Article  PubMed  CAS  Google Scholar 

  58. Hegele RA, Brunt JH, Connelly PW: A polymorphism of the angiotensinogen gene associated with variation in blood pressure in a genetic isolate. Circulation 1994, 90:2207–2212.

    PubMed  CAS  Google Scholar 

  59. Hegele RA, Brunt JH, Connelly PW: Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate Hypertension 1996, 27:308–312.

    PubMed  CAS  Google Scholar 

  60. Hegele RA, Brunt JH, Connelly PW: Genetic variation on chromosome 1 associated with variation in body fat distribution in men. Circulation 1995, 92:1089–1093.

    PubMed  CAS  Google Scholar 

  61. Tiret L, Ricard S, Poirier O, et al.: Genetic variation in relation to high blood pressure and myocardial infarction: the ECTIM study. J Hypertens 1995, 13:311–317.

    Article  PubMed  CAS  Google Scholar 

  62. Morise T, Katenchi Y, Takeda R: Rapid detection and prevalence of the variants of the angiotensinogen gene in patients with essential hypertension. J Intern Med 1995, 235:175–180.

    Article  Google Scholar 

  63. Yanai K, Saito T, Hirota K, et al.: Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcriptional initiation site affects its transcriptional activity. J Biol Chem 1996, 271:15981–15986. This study suggested the possible involvement of an ubiquitously expressed nuclear factor as a component of a more complex combination of transcription factors binding to the region situated between positions -25 and -1 before the transcription initiation site. In addition, competitive gel-shift and transfection experiments demonstrated differences of transcriptional activity according to the A-20C and C-18T polymorphisms.

    Article  PubMed  CAS  Google Scholar 

  64. Ishigami T, Umemura S, Tamura K, et al.: Essential hypertension and 5’ upstream core promoter region of human angiotensinogen gene. Hypertension 1997, 30:1325–1330.

    PubMed  CAS  Google Scholar 

  65. Hixson JE, Powers PK: Detection and characterization of new mutations in the human angiotensinogen gene. Hum Genet 1995, 96:110–112.

    Article  PubMed  CAS  Google Scholar 

  66. Inoue I, Rohrwasser A, Helin C, et al.: A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system. J Biol Chem 1995, 270:11430–11436.

    Article  PubMed  CAS  Google Scholar 

  67. Bouhnik J, Clauser E, Strosberg D, et al.: Rat angiotensinogen and des(angiotensin I)angiotensinogen: purification, characterization, and partial sequencing. Biochemistry 1981, 20:7010–7015.

    Article  PubMed  CAS  Google Scholar 

  68. Bohlender J, Menard J, Wagner J, et al.: Human renin-dependent hypertension in rats transgenic for human angiotensinogen. Hypertension 1996, 27:535–540.

    PubMed  CAS  Google Scholar 

  69. Gimenez-Roqueplo AP, Leconte I, Cohen P, et al.: The natural mutation Y248C of human angiotensinogen leads to abnormal glycosylation and altered immunological recognition of the protein. J Biol Chem 1996, 271:9838 9844.

    PubMed  Google Scholar 

  70. Saye JA, Lynch KR, Peach MJ: Changes in angiotensinogen messenger RNA in differentiating 3T3-F442A adipocytes. Hypertension 1990, 15:867–871.

    PubMed  CAS  Google Scholar 

  71. Ailhaud G: Molecular mechanisms of adipocyte differentiation. J Endocrinol 1997,155:201–202.

    Article  PubMed  CAS  Google Scholar 

  72. Frederich RC Jr, Kahn BB, Peach MJ, et al.: Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992, 19:339–344.

    PubMed  CAS  Google Scholar 

  73. Eggena P, Sowers J, Maxwell MH, et al.: Hormonal correlates of weight loss associated with blood pressure reduction. Clin Exp Hypertens 1991, 13:1447–1456.

    CAS  Google Scholar 

  74. Cooper R, Forrester T, Ogunbiyi O, Muffinda J: Angiotensinogen levels and obesity in four black populations. J Hypertens 1998, 16:571–575.

    Article  PubMed  CAS  Google Scholar 

  75. Schorr U, Blaschke K, Turan S, et al.: Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 1998, 16:1475–1480. First study to demonstrate strong correlations between plasma angiotensinogen levels and both body mass index and plasma leptin concentration.

    Article  PubMed  CAS  Google Scholar 

  76. Kanai H, Matsuzawa Y, Kotani K, et al.: Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 1990, 16:484–490.

    PubMed  CAS  Google Scholar 

  77. Aubert J, Darimont C, Safonova I, et al.: Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem J 1997, 328:701–706.

    PubMed  CAS  Google Scholar 

  78. Sutherland A, Cooper D, Howie P, et al.: The incidence of severe pre-eclampsia amongst mothers and mothers-in-law of pre-eclamptics and controls. Br J Obstet Gynaecol 1981, 88:785–789.

    PubMed  CAS  Google Scholar 

  79. Chesley LC, Cooper DW: Genetics of hypertension in pregnancy: possible single gene control of pre-eclampsia and eclampsia in the descendants of eclamptic women. Br J Obstet Gynaecol 1986, 93:898–903.

    PubMed  CAS  Google Scholar 

  80. Arngrimsson R, Bjornsson H, Geirsson R: Analysis of different inheritance patterns in preeclampsia/eclampsia ssyndrome. In Hypertension in Pregnancy. Edited by Rubin PC. Amsterdam: Elsevier; 1995:27–38.

    Google Scholar 

  81. Skinner SL, Lumbers ER, Symonds EM: Analysis of changes in the renin angiotensin system during pregnancy Clin Sci 1972, 42:479–488.

    PubMed  CAS  Google Scholar 

  82. Tewksbury DA, Dart RA: High molecular weight angiotensinogen levels in hypertensive pregnant women. Hypertension 1982, 4:729–734.

    PubMed  CAS  Google Scholar 

  83. Oxvig C, Haaning J, Kristensen L, et al.: Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma. J Biol Chem 1995, 270:13645–13651.

    Article  PubMed  CAS  Google Scholar 

  84. Morgan T, Craven C, Nelson L, et al.: Angiotensinogen T235 expression is elevated in decidual spiral arteries. J Clin Invest 1997, 100:1406–1415. Using an allele-specific ligation assay and a single nucleotide primer extension assay, this study compared T235 expression levels to M235 levels in decidual arteries of products of abortion in heterozygous women. With the two assays, the expression of theT235 allele was approximately twice that of the M235 allele, suggesting a new explanation for the association between this polymorphism and pregnancy-induced hypertension.

    Article  PubMed  CAS  Google Scholar 

  85. Takimoto E, Ishida J, Sugiyama F, et al.: Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 1996, 274:995–998.

    Article  PubMed  CAS  Google Scholar 

  86. Arngrimsson R, Purandare S, Connor M, et al.: Angiotensinogen: a candidate gene involved in preeclampsia? Nature Genet 1993, 4:114–115.

    Article  PubMed  CAS  Google Scholar 

  87. Ward K, Hata A, Jeunemaitre X, et al.: A molecular variant of angiotensinogen associated with pre-eclampsia. Nature Genet 1993, 4:59–61.

    Article  PubMed  CAS  Google Scholar 

  88. Kobashi G: A case-control study of pregnancy-induced hypertension with a genetic predisposition: association of molecular variant of angiotensinogen in the Japanese women. Hokaido Igaku Zaosshi 1995, 70:649–657.

    CAS  Google Scholar 

  89. Wilton AN, Kaye JA, Guo G, et al.: Is angiotensinogen a good candidate gene for preeclampsia? Clin Exp Hypertens 1995, 14:251–260.

    Google Scholar 

  90. Morgan L, Baker P, Pipkin FB, et al.: Pre-eclampsia and the angiotensinogen gene. Br J Obstet Gynaecol 1995, 102:489–490.

    PubMed  CAS  Google Scholar 

  91. Guo G, Wilton AN, Fu Y, et al.: Angiotensinogen gene variation in a population case-control study of preeclampsia/ eclampsia in Australians and Chinese. Electrophoresis 1997, 18:1646–1649.

    Article  PubMed  CAS  Google Scholar 

  92. Bernstein IM, Ziegler W, Stirewalt WS, et al.: Angiotensinogen genotype and plasma volume in nulligravid women. Obstet Gynecol 1998, 92:171–173.

    Article  PubMed  CAS  Google Scholar 

  93. Gimenez-Roqueplo AP, Celerier J, Schmid G, et al.: Role of cysteine residues in human angiotensinogen. Cys232 is required for angiotensinogen-pro major basic protein com plex formation. J Biol Chem 1998, 273:34480–34487. First demonstration of the presence of a disulfide bond between Cys 18 and Cys 138 of the mature angiotensinogen protein and of the possible influence of the M235T polymorphism on the formation of the high molecular weight form of angiotensinogen.

    Article  PubMed  CAS  Google Scholar 

  94. O’Byrne S, Caulfield M: Genetics of hypertension: therapeutic implications. Drugs 1998, 56:203–214.

    Article  PubMed  CAS  Google Scholar 

  95. Hunt SC, Cook NR, Oberman A, et al.: Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension. Hypertension 1998, 32:393–401. Genetic investigation of 1509 white male and female subjects participating in phase II of the Trials of Hypertension Prevention. According to the G-6A polymorphism, weak but significant decreases in diastolic blood pressure were observed at 36 months in the sodium reduction group.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U36, Collège de France, 3, rue d’Ulm, 75005, Paris, France

    Xavier Jeunemaitre MD, PhD, Anne-Paule Gimenez-Roqueplo MD, PhD, Jérôme Célérier PhD & Pierre Corvol MD

Authors
  1. Xavier Jeunemaitre MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne-Paule Gimenez-Roqueplo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jérôme Célérier PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre Corvol MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeunemaitre, X., Gimenez-Roqueplo, AP., Célérier, J. et al. Angiotensinogen variants and human hypertension. Current Science Inc 1, 31–41 (1999). https://doi.org/10.1007/s11906-999-0071-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-999-0071-0

Keywords

Search

Navigation